Moving MERS Therapies Forward

Scientists wonder whether they can obtain the resources to test experimental vaccines and treatments in humans.

Written byAmanda B. Keener
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

FLICKR, NIAID

South Korean officials today announced the end of the country’s recent Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak, but scientists studying the virus and others like it expect more outbreaks to follow.

“We think there will be other coronaviruses in the future that will be important and will need to be dealt with,” said Barney Graham, deputy director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID). In a paper published today (July 28) in Nature Communications, Graham and his colleagues described the antibody response to a vaccine candidate based on the MERS-CoV spike glycoprotein in mice, and characterized several murine virus-neutralizing monoclonal antibodies. The report follows on another study, published yesterday (July 27) in PNAS, in which researchers ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies